Cargando…
Evidence for secondary thrombotic microangiopathy in COVID-19
The causes of coagulopathy associated with COVID-19 disease are poorly understood. We aimed to investigate the relationship between markers of endothelial activation, intravascular hemolysis, coagulation, and organ damage in COVID-19 patients and study their association with disease severity and mor...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7587832/ https://www.ncbi.nlm.nih.gov/pubmed/33106812 http://dx.doi.org/10.1101/2020.10.20.20215608 |
_version_ | 1783600259157458944 |
---|---|
author | Sweeney, Joseph M. Barouqa, Mohammad Krause, Gregory J. Gonzalez-Lugo, Jesus D. Rahman, Shafia Gil, Morayma Reyes |
author_facet | Sweeney, Joseph M. Barouqa, Mohammad Krause, Gregory J. Gonzalez-Lugo, Jesus D. Rahman, Shafia Gil, Morayma Reyes |
author_sort | Sweeney, Joseph M. |
collection | PubMed |
description | The causes of coagulopathy associated with COVID-19 disease are poorly understood. We aimed to investigate the relationship between markers of endothelial activation, intravascular hemolysis, coagulation, and organ damage in COVID-19 patients and study their association with disease severity and mortality. We conducted a retrospective study of 181 hospitalized COVID-19 patients randomly selected with equal distribution of survivors and non-survivors. Patients who died had significantly lower ADAMTS13 activity, significantly higher LDH, schistocytes and von Willebrand Factor levels compared to patients discharged alive. Only 30% of patients with an initial ADAMTS13 activity <43% survived vs. 60% with ADAMTS13 ≥43% who survived. In conclusion, COVID-19 may manifest as a TMA-like illness in a subset of hospitalized patients. Presence of schistocytes on admission may warrant a work-up for TMA. These findings indicate the need for future investigation to study the relationship between endothelial and coagulation activation and the efficacy of TMA treatments in COVID-19. |
format | Online Article Text |
id | pubmed-7587832 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Cold Spring Harbor Laboratory |
record_format | MEDLINE/PubMed |
spelling | pubmed-75878322020-10-27 Evidence for secondary thrombotic microangiopathy in COVID-19 Sweeney, Joseph M. Barouqa, Mohammad Krause, Gregory J. Gonzalez-Lugo, Jesus D. Rahman, Shafia Gil, Morayma Reyes medRxiv Article The causes of coagulopathy associated with COVID-19 disease are poorly understood. We aimed to investigate the relationship between markers of endothelial activation, intravascular hemolysis, coagulation, and organ damage in COVID-19 patients and study their association with disease severity and mortality. We conducted a retrospective study of 181 hospitalized COVID-19 patients randomly selected with equal distribution of survivors and non-survivors. Patients who died had significantly lower ADAMTS13 activity, significantly higher LDH, schistocytes and von Willebrand Factor levels compared to patients discharged alive. Only 30% of patients with an initial ADAMTS13 activity <43% survived vs. 60% with ADAMTS13 ≥43% who survived. In conclusion, COVID-19 may manifest as a TMA-like illness in a subset of hospitalized patients. Presence of schistocytes on admission may warrant a work-up for TMA. These findings indicate the need for future investigation to study the relationship between endothelial and coagulation activation and the efficacy of TMA treatments in COVID-19. Cold Spring Harbor Laboratory 2020-10-23 /pmc/articles/PMC7587832/ /pubmed/33106812 http://dx.doi.org/10.1101/2020.10.20.20215608 Text en http://creativecommons.org/licenses/by/4.0/It is made available under a CC-BY 4.0 International license (http://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Sweeney, Joseph M. Barouqa, Mohammad Krause, Gregory J. Gonzalez-Lugo, Jesus D. Rahman, Shafia Gil, Morayma Reyes Evidence for secondary thrombotic microangiopathy in COVID-19 |
title | Evidence for secondary thrombotic microangiopathy in COVID-19 |
title_full | Evidence for secondary thrombotic microangiopathy in COVID-19 |
title_fullStr | Evidence for secondary thrombotic microangiopathy in COVID-19 |
title_full_unstemmed | Evidence for secondary thrombotic microangiopathy in COVID-19 |
title_short | Evidence for secondary thrombotic microangiopathy in COVID-19 |
title_sort | evidence for secondary thrombotic microangiopathy in covid-19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7587832/ https://www.ncbi.nlm.nih.gov/pubmed/33106812 http://dx.doi.org/10.1101/2020.10.20.20215608 |
work_keys_str_mv | AT sweeneyjosephm evidenceforsecondarythromboticmicroangiopathyincovid19 AT barouqamohammad evidenceforsecondarythromboticmicroangiopathyincovid19 AT krausegregoryj evidenceforsecondarythromboticmicroangiopathyincovid19 AT gonzalezlugojesusd evidenceforsecondarythromboticmicroangiopathyincovid19 AT rahmanshafia evidenceforsecondarythromboticmicroangiopathyincovid19 AT gilmoraymareyes evidenceforsecondarythromboticmicroangiopathyincovid19 |